BKT 300

Drug Profile

BKT 300

Alternative Names: BKT300

Latest Information Update: 28 Jan 2016

Price : $50

At a glance

  • Originator Biokine Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 28 Jan 2016 Preclinical trials in Solid tumours in Israel (unspecified route) prior to January 2016 (Biokine pipeline, January 2016)
  • 28 Jan 2016 BKT 300 is available for licensing as of 28 Jan 2016. http://biokine.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top